IDRX-42 clinical trials
Also written Velzatinib, GSK6042981 and IDRX-42.
How each study uses IDRX-42 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IDRX-42 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
GlaxoSmithKline (7) · IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test IDRX-42.
- Jan 2027A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsPhase 1 · GlaxoSmithKline
- Mar 2027First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsPhase 1 · IDRX, Inc., a wholly owned subsidiary of GSK, LLC
- Sep 2027A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibPhase 1 · GlaxoSmithKline
- Nov 2027A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibPhase 2 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses IDRX-42 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingPhase 3GlaxoSmithKlineNCT07585266Written as Velzatinib
- A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibNot yet recruitingPhase 1GlaxoSmithKlineNCT07867171Written as Velzatinib
- A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNot yet recruitingPhase 1GlaxoSmithKlineNCT07862114Written as Velzatinib
- A Study to Investigate the Effects of Impaired Hepatic Function on VelzatinibNot yet recruitingPhase 1GlaxoSmithKlineNCT07859735Written as Velzatinib
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyRecruitingPhase 3GlaxoSmithKlineNCT07218926Written as IDRX-42
- A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRecruitingPhase 2GlaxoSmithKlineNCT07689201Written as Velzatinib
- A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)Not yet recruitingPhase 2GlaxoSmithKlineNCT07843641Written as Velzatinib
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruitingPhase 1IDRX, Inc., a wholly owned subsidiary of GSK, LLCNCT05489237Written as IDRX-42
Codes
What other systems call IDRX-42 · ClinicalTrials.gg INT002061
- MeSH (NLM) C000729878IDRX-42One source ClinicalTrials.gov
- UNII (FDA) Y6UHU32G5ZVELZATINIBConfirmed FDA, Wikidata
- Wikidata Q131926975IDRX-42Confirmed FDA, Wikidata
- DrugBank DB18087One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729878 | IDRX-42 | One source ClinicalTrials.gov |
| UNII (FDA) | Y6UHU32G5Z | VELZATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q131926975 | IDRX-42 | Confirmed FDA, Wikidata |
| DrugBank | DB18087 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.